| VIVUS posts loss on testing costs, lower revenue Forbes VIVUS is also running late-stage trials of the obesity drug candidate Qnexa, and plans to file for regulatory approval by the end of 2009. ... See all stories on this topic |
| VIVUS Reports Second Quarter 2009 Financial Results PR Newswire (press release) Spending on Qnexa, our investigational product for obesity, was consistent quarter over quarter. Total revenue for the second quarter of 2009 was $14.7 ... See all stories on this topic |
--
Best regards
Nick Johnson
Http://www.thegoldenfuture.com
YOU CAN GET THE BODDY YOU WANT
TAGS:Weigh
waight
wieght
Weigth
weigt
rapid weight loss
loose weight
weightloss